Compare SkyWest Inc (SKYW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SkyWest Inc vs 10X Genomics Inc — how do they compare? SkyWest Inc trades at $95.26 (market cap $3.94B), while 10X Genomics Inc trades at $47.48 (market cap $5.48B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| SKYW | TXG | |
|---|---|---|
Market Cap | $3.94B | $5.48B |
Sector | Technology | Health |
52-Week High | $123.72 | $45.80 |
52-Week Low | $78.40 | $11.34 |
Enterprise Value | $5.79B | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $99.34, up 2.17% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 9.52 and net income margin of 10.42%. Recent earnings beat expectations in Q1 2026, and analyst consensus is a buy with a $109.33 price target. The company announced a new president and COO in July 2026, signaling operational focus amid industry fuel cost pressures.
The outlook is positive given undervaluation and earnings momentum, but risks include elevated jet fuel expenses impacting airline profitability. Investor sentiment is supported by institutional buying and lack of sell ratings, though macroeconomic headwinds remain a key watchpoint for near-term performance.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
